Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Arcadia Biosciences (Nasdaq: RKDA) said it closed a $4 million private placement under Nasdaq rules, selling 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options to buy up to 3,883,496 shares each at $1.03/share. Gross proceeds were about $4 million. H.C. Wainwright & Co. was placement agent; proceeds will fund working capital and general corporate purposes.
How this was made
The 30-second read
Why it matters
Traders should model dilution from the 3,883,496 share equivalent issuance and consider future overhang from Series A-1/A-2 option exercises (exercise price $0.91) and the timing constraints tied to stockholder approval and resale registration.
Market read
Closed financing at $1.03/share with $0.91 exercise options; the key tradable variable is dilution/overhang versus reduced funding-risk.
What to watch
Series A-1 requires stockholder approval to become exercisable; timing of approval and the resale registration process can delay/shape when dilution actually hits the tape.
Background
Arcadia announced and then closed an at-the-market priced private placement under Nasdaq rules, using common stock and preferred investment options (with pre-funded warrants in lieu).
Ticker impact
Arcadia Biosciences closed a $4M at-the-market private placement for 3,883,496 shares (or pre-funded warrants) at $1.03/share, plus Series A-1/A-2 options.
Likely near-term pressure/volatility from dilution overhang, partially offset by cash proceeds; direction depends on whether the market views the financing as sufficient runway.
The article discloses the closing, pricing, share count, and option exercise terms, which directly inform dilution and future selling/exercise risk.
Market effects
Adds another small-cap biotech/wellness financing datapoint; may reinforce risk premium for pre-revenue/early-stage issuers using ATM + preferred option structures.
No specific regional spillover beyond US microcap sentiment.
Limited; primarily affects RKDA’s capital structure and investor base.
Counterpoint
If the company’s cash runway was the key overhang, the $4M gross proceeds could reduce near-term funding risk more than the market discounts dilution.
Key entities
- issuerArcadia Biosciences, Inc.
Nasdaq-listed company (RKDA) that closed the $4M private placement and disclosed pricing and option exercise terms.
- placement_agentH.C. Wainwright & Co.
Exclusive placement agent for the offering.
